EyePoint Pharmaceuticals has fully enrolled its two Phase 3 trials in wet age-related macular degeneration (LUGANO and LUCIA), initiated a pivotal two-trial Phase 3 program in diabetic macular edema (COMO and CAPRI) with first dosing slated for early 2026, and raised $172.5 million in an oversubscribed equity offering that extends cash runway into the fourth quarter of 2027. Topline data from LUGANO are expected mid-2026, with LUCIA to follow. The company is advancing DURAVYU, a bioerodible, sustained-release intravitreal formulation of the TKI vorolanib, with six-month redosing in DME and a positioning thesis built on injection burden reduction and a multi-target mechanism that addresses both VEGF-driven vascular leakage and IL-6–mediated inflammation.
The strategic question is whether a twice-yearly sustained-release TKI can carve out share in a retina market reshaped by extended-interval anti-VEGF biologics and the return of device and gene therapy options. Regeneron and Roche have already pushed office-based injection intervals to 12–16 weeks in large patient segments, while Susvimo reintroduced an implant-based, refillable approach. DURAVYU’s claim rests on two differentiators: a practical in-office, long-acting profile that targets two biological drivers of disease, and a regulatory path in DME grounded in non-inferiority to on-label aflibercept 2 mg on BCVA at weeks 52 and 56. If that bet holds, EyePoint could become the first to file among investigational sustained-release programs in wet AMD and the only TKI in late-stage development for DME, opening access to large, durable markets where adherence and clinic capacity remain pain points.
For patients, fewer injections with maintained visual outcomes is the core value proposition. For retina specialists facing capacity constraints and high no-show rates, a six-month redose cadence could ease operational pressure without the surgical footprint required by implants. For payers, durability must translate into a lower total cost of care. Non-inferiority on vision endpoints will help, but formulary access will hinge on clear evidence of reduced rescue injections, procedure utilization, and sustained anatomical control in real-world settings. The choice of aflibercept 2 mg as the DME comparator is regulatorily orthodox, yet Commercial teams will need to position against the increasingly common use of higher-dose aflibercept and faricimab’s dual-pathway profile, both of which have established outcomes and contracting muscle.
EyePoint’s preclinical signal of IL-6 pathway modulation gives Medical Affairs a narrative beyond VEGF, but translation from in vitro JAK1 inhibition to clinically meaningful inflammation control remains to be proven at scale. The company’s Phase 2 VERONA data in DME suggested durability and vision gains with a single dose; Phase 3 must replicate that performance across both treatment-naïve and previously treated patients while maintaining a clean intraocular safety profile. The retina field has long memories of TKI and sustained-delivery stumbles; even a small safety imbalance could slow adoption among procedure-averse patients and risk-sensitive clinics.
Financially, EyePoint is spending to win. Third-quarter revenue fell year over year as legacy licensing tails off, operating expenses rose to fund Phase 3 execution, and the company posted a wider net loss. The October raise, at scale and fully subscribed, signals investor appetite for credible durability plays that avoid the surgical complexity of implants and the permanence and monitoring demands of gene therapy. With cash now guiding through key 2026 readouts, the company has the runway to prosecute the strategy and prepare for access and launch.
The next 12 months will determine whether DURAVYU becomes the practical middle ground between high-frequency injections and invasive long-acting modalities. If EyePoint delivers non-inferiority with a compelling rescue profile and a clean safety signal, will payers reward a six-month cadence with favorable tiering, and can the company convert that into preferential use in DME before gene therapy claims more of the durability narrative?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
